Altimmune posts higher than expected Q3 loss
Overview
US biopharma firm's Q3 net loss and loss per share missed analyst expectations
Company ended Q3 with $480 mln in cash, cash equivalents and investments
Higher R&D and G&A expenses driven by clinical trials and compensation costs
Outlook
PERFORMA Phase 3 MASH trial progressing as planned; 52-week topline data readout expected in 2029
End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026
Topline data from RESTORE Phase 2 ALD trial expected in second half of 2027
Result Drivers
CLINICAL TRIAL SPENDING - Co said higher R&D expenses were primarily due to ongoing PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD
COMPENSATION AND PROFESSIONAL SERVICES - Co said higher G&A expenses were mainly due to increased compensation expenses and professional services
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | Miss | $0.15 | $0.14 (9 Analysts) |
Q3 Net Loss | Miss | $31.61 mln | $25.48 mln (8 Analysts) |
Q3 Income from Operations | Miss | -$35.71 mln | -$28.42 mln (7 Analysts) |
Q3 Loss Per Basic Share | $0.15 | ||
Q3 Operating Expenses | $35.71 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Altimmune, Inc. is $15.00, about 677.2% above its November 11 closing price of $1.93
Reuters Recommended Reads
Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs
Nov 9 - Trevi Therapeutics Q3 net loss widens on higher R&D costs
Nov 12 - Century Therapeutics Q3 net loss narrows, beats analyst expectations
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)